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S U M M A R Y
Objective: To evaluate non-inferiority of three doses of Quinvaxem in a compact preﬁlled auto-disabled
(cPAD) injection system versus Quinvaxem in a single-dose vial administered with conventional syringe
in terms of seroconversion/seroprotection rates for all antibodies (anti-hepatitis B (HB), anti-
Haemophilus inﬂuenzae type b polyribosylribitol phosphate (Hib PRP), anti-diphtheria, anti-tetanus,
anti-Bordetella pertussis) at 1 month after primary vaccination.
Methods: Four hundred healthy infants aged 4265 days were randomized (1:1) to receive Quinvaxem
in cPAD or single-dose vial at 6, 10, and 12 weeks of age. Blood samples were collected before vaccination
and at 1 month after the third dose to determine seroconversion/seroprotection rates. Safety was
assessed from solicited and unsolicited adverse events and serious adverse events (SAEs).
Results: Of the 400 infants randomized, 395 (98.8%) received all three vaccine doses. In the cPAD vs.
single-dose vial groups, seroprotection rates against Hib PRP (both 98.5%), HB (92.9% vs. 93.4%),
diphtheria (100% vs. 99%), and tetanus toxoids (both 100%), and seroconversion against B. pertussis
(95.4% vs. 97%) were 92% at 1 month after the third vaccination (lower limits of 95% conﬁdence
intervals simultaneously greater than 10%). Geometric mean concentrations exceeded seroprotection/
seroconversion thresholds by large margins. The incidences of induration and erythema were
comparable between the groups; tenderness was slightly higher in the cPAD group (85.5% vs. 76.5%). No
vaccine-related SAEs occurred.
Conclusions: Quinvaxem in cPAD was non-inferior to single-dose vial with respect to seroprotection/
seroconversion rates for all antibodies. Both presentations were well-tolerated.
 2016 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Immunization is a cost-effective and life-saving intervention
that prevents an estimated two to three million deaths every year
from vaccine-preventable diseases.1,2 The aim of the World Health
Organization (WHO) Expanded Programme on Immunization (EPI)
is to protect children against life-threatening diseases like
tuberculosis, diphtheria, neonatal tetanus, whooping cough,* Corresponding author. Tel./Fax: +63 2 772 4916.
E-mail address: lerosecap@gmail.com (M.R.Z. Capeding).
http://dx.doi.org/10.1016/j.ijid.2016.02.015
1201-9712/ 2016 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/4.0/).poliomyelitis, and measles, as well as hepatitis B3 and Haemophilus
inﬂuenzae type b (Hib).4 According to the WHO, approximately
22.6 million children worldwide did not receive the full three doses
of diphtheria–tetanus–pertussis (DTP3) vaccine in 2012.2 Likewise,
globally only 45% of children received three doses of Hib vaccine
in 2012.5
Pentavalent vaccines remain the cornerstone of the EPI because
of their numerous advantages over separate injections, including
protection against ﬁve diseases in one injection (DTP, hepatitis B
(HB), and Hib), better immunization coverage, simple, easy-to-
administer fully liquid formulations, fewer injections and less
distress for children, lower shipping and transport costs, fewerious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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for Vaccines and Immunisation (GAVI) aimed to increase the
coverage level of pentavalent vaccine from 53% at the end of
2013 to 77% by the end of 2015.7 To date, the WHO has prequaliﬁed
six pentavalent vaccines for use in EPI programs, including
Quinvaxem in 2006.8
Quinvaxem (DTwP–HepB–Hib) is a fully liquid pentavalent
combination vaccine consisting of inactivated hepatitis B surface
antigen (HBsAg), Hib conjugated to Corynebacterium diphtheriae
cross-reacting material 197 (CRM197–Hib), tetanus toxoid, diph-
theria toxoid, and whole-cell pertussis antigens.9,10 The vaccine is
indicated for active immunization of infants and toddlers against
diseases caused by ﬁve different pathogens: hepatitis B virus, C.
diphtheriae, Clostridium tetani, Bordetella pertussis, and Hib.
Quinvaxem has been shown to be protective, immunogenic, and
well-tolerated in several clinical studies.10–15
The Becton Dickenson Uniject is a compact autodisposable,
preﬁlled, single-use injection system, originally developed by
PATH in 1987 to promote vaccination in developing countries in
response to a recognized need for the development of single-use,
auto-disable injection systems to reduce cross-contamination and
the risk of blood-borne infections, vaccine wastage, and missed
vaccination opportunities.16–18 Currently, the WHO has prequa-
liﬁed both tetanus and HB vaccines in Uniject presentations.16 A
new presentation of Quinvaxem has also been developed in this
compact preﬁlled auto-disabled (cPAD) injection system. The
formulation for Quinvaxem in cPAD is the same as the fully liquid
pentavalent vaccine that is available in a single-dose vial. The cPAD
injection system is expected to have considerable advantages in
the ﬁeld of vaccination, particularly in difﬁcult-to-reach settings,
e.g., hard-to-reach communities19–21 for which there are unique
challenges in terms of resources and logistics. It also offers
simpliﬁed vaccine administration, as well as additional beneﬁts
such as reduced vaccine and medical wastage, reduced possibility
of contamination risk and disease transmission, and a removal of
the need for vaccine reconstitution before use.
Quinvaxem injection is a ready-to-use, preservative-free, fully
liquid pentavalent vaccine that gained WHO pre-qualiﬁcation
status in 2006. Quinvaxem was found to be highly immunogenic in
each of the primary vaccination studies and was also shown to be
suitable as a booster, with the advantage that it could be given
concomitantly with measles vaccine, in four clinical trials and one
post-marketing observational study.22 Quinvaxem has been
included in EPI vaccination programs to further support the needs
of EPI vaccination processes and developing countries. A simple,
all-in-one, compact, preﬁlled, auto-disabled Uniject injection
system is a potentially optimized new presentation for Quin-
vaxem; the cPAD contains the same vaccine formulation as the
approved and marketed product.
Uniject is a cPAD injection system that was developed by PATH
and subsequently marketed by Becton Dickinson.23 It was initially
developed in response to the WHO and other organizations
recognizing a great need for the development of single-use, auto-
disable injection systems to reduce cross-contamination and the
risk of blood-borne infections (due to syringe/needle re-use), to
reduce vaccine wastage, and to reduce missed vaccination
opportunities.23,24 Uniject is well-established as a successful
system for the delivery of injectable contraceptives, vaccines,
antibiotics, and uterotonic drugs, and around nine million doses of
tetanus toxoid vaccine and 75 million doses of HB vaccine have
been distributed using the Uniject presentation.23–26
This study on Quinvaxem in cPAD was conducted to demon-
strate non-inferiority of three doses of Quinvaxem in cPAD to three
doses of Quinvaxem in single-dose vials with respect to antibody
seroprotection/seroconversion rates (anti-hepatitis B surface
antigen (anti-HBs), anti-Hib polyribosylribitol phosphate (HibPRP), anti-diphtheria toxoid, anti-tetanus toxoid, and anti-B.
pertussis) at 1 month after completion of the 6–10–14 week
primary vaccination course. The safety proﬁle was also evaluated.
2. Methods
2.1. Study population
Healthy infants of both sexes aged between 42 and 64 days (at
the time of ﬁrst vaccination), immunized with the HB vaccination
within 48 h after birth, with no obvious health problems as
established by medical history and/or clinical examination, and
eligible for the local EPI program, were enrolled in the study.
Exclusion criteria included known/suspected immune function
impairment, known HIV positivity, systemic immunosuppressive
therapy at the time of screening or within 1 month before study
entry (except inhaled and topical steroids), previous treatment
with a parenteral immunoglobulin preparation and/or blood
products, vaccination against Hib and/or DTP, history of anaphy-
laxis or hypersensitivity to any vaccine ingredient, or presence of
clinically signiﬁcant acute infection or acute illness.
The institutional review board approved the protocol and the
study was conducted in accordance with the ethical principles that
have their origin in the Declaration of Helsinki and that are
consistent with Good Clinical Practice and applicable regulatory
requirements. Parents/legal guardians gave written informed
consent before study enrollment. The study is registered at
ClinicalTrials.gov (NCT01349283).
2.2. Study design and vaccination schedule
This was a phase 3, open-label, randomized, comparator-
controlled, single-center non-inferiority study conducted between
September 13, 2013 and March 21, 2014 at the Research Institute
for Tropical Medicine, Alabang, Muntinlupa City, Philippines.
Infants were randomized 1:1 to receive three intramuscular
doses of Quinvaxem presented either in cPAD or in single-dose
vials into the anterolateral region of the thigh at 6, 10, and
14 weeks of age. Randomization was performed using computer-
generated randomization codes, with each infant receiving a
sealed booklet containing the randomization ID. A blocked
randomization scheme was adopted to achieve balance between
the two study groups. All infants were vaccinated using a
conventional needle (23 gauge  1’’ (25 mm) length) at visits 1,
2, and 3. The active study phase lasted for 12 weeks for all infants.
Four vaccinators performed the vaccinations throughout the study
(approximately 100 infants each), and all three doses were
administered by the same trained and qualiﬁed vaccinator once
an infant had been randomized.
Each 0.5-ml dose of Quinvaxem in cPAD (lot number X9161009;
Berna Biotech Korea Corporation) and in single-dose vials (lot
number 1453138; Berna Biotech Korea Corporation) contained
30 IU diphtheria toxoid, 60 IU tetanus toxoid, 4 IU inactivated
B. pertussis, 10 mg Hib polysaccharide conjugated to CRM197
protein (25 mg), and 10 mg HBsAg.
2.3. Study assessments
2.3.1. Primary immunogenicity endpoint
The primary objective was to demonstrate non-inferiority of
three doses of Quinvaxem in cPAD to three doses of Quinvaxem in
single-dose vials with respect to antibody seroprotection/serocon-
version rates (anti-HBs, anti-Hib PRP, anti-diphtheria toxoid, anti-
tetanus toxoid, and anti-B. pertussis) at 1 month after completion of
the primary vaccination course.
Table 1
Demographics and baseline characteristics (ITT population)
Characteristics cPAD
(N = 197)
Single-dose
(N = 198)
Total
(n = 395)
Sex, n (%)
Male 103 (52.3) 100 (50.5) 203 (51.4)
Female 94 (47.7) 98 (49.5) 192 (48.6)
Age (weeks), mean (SD) 6.93 (0.94) 6.93 (1.0) 6.93 (0.96)
Weight (kg), mean (SD) 4.64 (0.60) 4.66 (0.65) 4.65 (0.62)
Prior BCG vaccination, n (%)
Yes 29 (14.7) 31 (15.7) 60 (15.2)
No 168 (85.3) 167 (84.3) 335 (84.8)
BCG, bacillus Calmette–Gue´rin; cPAD, compact preﬁlled auto-disabled system; ITT,
intention-to-treat; SD, standard deviation.
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The major secondary immunogenicity endpoints were (1) the
percentage of infants with anti-Hib PRP titers 1.0 mg/ml and (2)
geometric mean concentrations (GMCs) for anti-HBs, anti-diph-
theria toxin, anti-tetanus toxin, anti-B. pertussis, and anti-Hib PRP
at 1 month after the third vaccination.
2.3.3. Serology evaluations
A 3-ml blood sample was drawn by venous puncture immedi-
ately prior to the ﬁrst vaccine dose (visit 1) and at 1 month after the
third vaccine dose (visit 4). HB antibodies were analyzed using an
indirect ELISA (Enzygnost; Siemens Diagnostics at Novartis Vaccines
and Diagnostics GmbH, Marburg, Germany), with seroprotection
deﬁned as an HB antibody concentration 10 IU/ml. A competitive
ELISA was used to measure antibodies against Hib PRP (VaccZyme;
The Binding Site Ltd, UK), with seroprotection rates determined
using two cut-off levels (0.15 mg/ml and 1.0 mg/ml). An indirect
ELISA was used for diphtheria and tetanus toxoid antibodies
(Virotech; Sekisui Diagnostics or Sekisui Virotech GmbH (Russel-
sheim, Germany)), with seroprotection deﬁned as a titer level 0.1
IU/ml. B. pertussis antibodies were analyzed using a whole cell IgG
ELISA (University of Turku, Finland). There is no international
standard deﬁnition of seroprotection for B. pertussis. Therefore, to
determine a signiﬁcant immune response to vaccination, serocon-
version was deﬁned as either a concentration 20 EU/ml or a 4-
fold increase from the pre-vaccination level.
2.3.4. Safety and tolerability
Each infant’s parent/legal guardian documented solicited local
adverse events (AEs) (tenderness, erythema, and induration) and
body temperature in a diary for 5 days following vaccination (i.e.,
on the day of vaccination and for 4 days thereafter), along with any
unsolicited AEs. Fever was deﬁned as a body temperature 38 8C.
Any other unsolicited AEs were also recorded at each visit from
responses to non-leading questions by the investigator. Serious
adverse events (SAEs) were collected throughout the study period.
2.4. Statistical methods
The non-inferiority of Quinvaxem in cPAD compared with
Quinvaxem in single-dose vials was demonstrated using the
Newcombe–Wilson score method if the lower limits of all two-
sided 95% conﬁdence intervals (CIs) of the differences in
seroprotection/seroconversion rates between the two groups were
simultaneously greater than –10%. The GMCs and corresponding
95% CIs (normal approximation) were calculated from log10-
transformed concentrations. GMC fold-increases (within-group
comparisons) and GMC ratios (between-group comparisons) are
presented together with the corresponding two-sided 95% CIs
(normal approximation) for each antigen. The immunogenicity
analysis was performed on the according-to-protocol (ATP)
analysis set, deﬁned as the set of all infants who received all
three doses and did not have any major protocol violations. The
intention-to-treat (ITT) analysis set was deﬁned as the set of all
infants who had at least one vaccination and had a post-baseline
measurement for at least one antigen.
2.4.1. Sample size
Assuming a 95% seroprotection/seroconversion rate for each
antigen in each group and a clinically signiﬁcant non-inferiority
limit of –10%, a sample size of 360 evaluable infants (randomized in a
1:1 ratio) was required to demonstrate non-inferiority of Quin-
vaxem in cPAD compared to Quinvaxem single-dose vials with an
overall power of >90% and a one-sided signiﬁcance level of 2.5%.
Assuming a dropout rate of approximately 10%, 400 infants in
total were randomized 1:1 (200 infants in each group). The samplesize was determined using the Newcombe–Wilson score method
to construct the CI (nQuery statistical software version 6.0).
3. Results
3.1. Study disposition and clinical characteristics
Of the 400 infants randomized, 200 were vaccinated with
Quinvaxem in cPAD and 200 with Quinvaxem in single-dose vials
using a conventional syringe. Altogether 395 (98.9%) infants
completed the entire study; 197 (98.5%) infants in the cPAD group
and 198 (99%) infants in the single-dose vials group received all
three vaccine doses. Five infants discontinued the study because
their parents withdrew consent (three (1.5%) in the cPAD group
and one (0.5%) in the single-dose group) or due to migration from
the study area (one (0.5%) in the single-dose group) (Figure 1).
A total 393 (98.3%) infants were included in the ATP analysis set,
196 (98%) in the cPAD group and 197 (98.5%) in the single-dose
vials group. Four infants from the cPAD group and three from the
single-dose vials group were excluded from the ATP analysis set as
they did not receive all three doses, or had a missing post-baseline
serum level, or due to major protocol violations. Overall, 51.4% of
the infants were male and 48.6% were female, and all were Asian
(Table 1). The median weight in both groups was 4.65 kg. Median
age was 6.5 weeks in the cPAD group and 6.4 weeks in the single-
dose group. In total, 15.2% of infants had received a prior bacillus
Calmette–Gue´rin (BCG) vaccination; none had previously used
immunosuppressants or corticosteroids.
3.2. Immunogenicity analysis
3.2.1. Primary immunogenicity endpoint
One month after the third dose, the two groups exhibited
similar seroprotection/seroconversion rates for tetanus toxoid
(100%), and 92.9% of cPAD infants and 93.4% of single-dose infants
achieved seroprotection against HB. Seroconversion against B.
pertussis was achieved in 95.4% of infants in the cPAD group and
97% in the single-dose group. For diphtheria, 100% of cPAD infants
and 99% of single-dose infants were seroprotected at 1 month after
the third dose. The percentage of infants with anti-Hib PRP titers
0.15 mg/ml was 98.5% in both groups (Table 2). Since the lower
limits of all these 95% CIs were simultaneously greater than 10%,
non-inferiority of the cPAD group compared with the single-dose
vial group was demonstrated. To assess the robustness of these
results, the same analysis was performed on the ITT analysis set
(Table 3). The results were similar in the ITT analysis set, assuring
consistency of the results between the two analysis sets.
3.2.2. Secondary immunogenicity endpoint
One month after the third vaccine dose (day 85), GMCs for all
antibodies in both groups exceeded the seroprotection/seroconver-
sion thresholds markedly (Table 4). Anti-Hib PRP and anti-diphtheria
Second vaccin ation, day 29  
Quinv axe m cPA D
n = 197 
Infants en rolled  and  randomi zed 
N = 400 
Pre-vaccination blood  sampling
First vaccinat ion, day 1 
Quinv axe m cPAD
n = 200
First vaccinat ion,  day  1 
Quinv axe m sing le-dos e 
n = 200
1 month  post-vaccination 
blo od sampling,  day 85
Complete d stud y: 197 (98.5 %) 
  Total discontinued:   3 (1.5%)  
    Consent wit hdrawal:  3 (1.5%)
  Exclu ded fr om: 
   Safety  analysis:  0 
   ITT  analysis:  3 (1.5%)  
   ATP  analysis:  4 (2.0%) 
Third  vacc ination,  day 57 
Quinv axe m cPAD
n = 197 
Second vaccin ation, day 29  
Quinv axe m sing le-dos e 
n = 199 
Third  vacc ination,  day 57 
Quinv axe m sing le-dos e 
n = 198
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blo od sampling,  day  85
Completed study:  198 (9 9.0%) 
  Total discontinued:  2 (1.0%)  
    Con sent wit hdrawal:  1 (0.5%)  
   Migrated/ moved:   1 (0.5%) 
  Exclu ded fr om: 
   Safety  analysis:  0 
   ITT  analysis:  2 (1. 0%)  
   ATP  analysis:  3 (1.5%) 
Discontinued:   
Consent withd rawal:  3 (1.5%)  
Discontinued:   
Consent withd rawal:  1 (0.5%)  
Discontinued:   
Infant  migrated:  1 (0.5%)  
Figure 1. Disposition of the infants (ATP, according-to-protocol; ITT, intention-to-treat; N is the number of subjects in the speciﬁed category; percentages are based on the
total number of randomized infants in each group).
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and Quinvaxem in single-dose vials (GMC ratios 1.04 and 0.99,
respectively). For tetanus and pertussis, antibody GMCs in the single-
dose group were numerically higher (both GMC ratios were 0.9). For
HB, antibody GMCs were numerically higher in the cPAD group (GMC
ratio 1.1). Fold-increases in antibody GMCs from day 1 to day 85 were
numerically higher in the single-dose group for all antigens except
tetanus. For the ATP population, there were slightly more responders
in the single-dose group (176; 89.3%) than in the cPAD group (172;
87.8%). The logistic regression analysis on responder rates adjusted for
vaccinator showed no inﬂuence due to vaccinator (Table 5).
3.3. Safety
The overall frequency of AEs was similar in the two groups
(Table 6). A total of 175 (87.5%) infants in the cPAD group and 169(84.5%) infants in the single-dose vial group exhibited at least one
solicited local AE when events after all three doses were combined.
Tenderness was the most common solicited local AE and was
experienced by more infants in the cPAD group (171; 85.5%) than
in the single-dose group (153; 76.5%). The frequency of induration
was similar in the cPAD and single-dose groups (74 (37.0%) vs. 76
(38.0%) infants); erythema was observed more frequently in the
single-dose group (61; 30.5%) than in the cPAD group (52; 26.0%).
Frequencies for all local solicited AEs in both groups were highest
after the ﬁrst dose and decreased after the second and third doses
(data not shown). Fever based on diary-recorded body tempera-
ture was reported in 42.5% of infants in the cPAD group and 41.5%
of infants in the single-dose group.
Overall, 131 (65.5%) infants in the cPAD group and 138 (69.0%)
infants in the single-dose group experienced unsolicited AEs. The
most commonly experienced unsolicited AEs, irrespective of causal
Table 2
Seroprotection/seroconversion rate: ATP populationa,b,c
Seroprotection/
seroconversion
cPAD
(N = 196)
n (%)
Single-dose
(N = 197)
n (%)
Diff. (95% CId)
Hib
Baseline (day 1) 137 (69.9) 153 (77.7)
Visit 4 (day 85) 193 (98.5) 194 (98.5) 0.0 (3.05, 3.02)
Diphtheria
Baseline (day 1) 46 (23.5) 39 (19.8)
Visit 4 (day 85) 196 (100) 195 (99.0) 1.0 (1.04, 3.63)
Tetanus
Baseline (day 1) 181 (92.3) 189 (95.9)
Visit 4 (day 85) 196 (100) 197 (100) 0.0 (1.92, 1.91)
Hepatitis B
Baseline (day 1) 54 (27.6) 51 (25.9)
Visit 4 (day 85) 182 (92.9) 184 (93.4) 0.5 (5.78, 4.66)
Pertussis
Visit 4 (day 85) 187 (95.4) 191 (97.0) 1.5 (5.78, 2.51)
ATP, according-to-protocol; CI, conﬁdence interval; cPAD, compact preﬁlled auto-
disabled system; Hib, Haemophilus inﬂuenzae type b.
a ATP population: The set of all intention-to-treat infants who received all three
vaccinations, who had at least one blood sample with one post-baseline
measurement for at least one antigen, and who had no major protocol violations.
b N is the total number of infants in each group and n is the total number of
infants meeting the event. Percentages are based on the total number of infants in
each vaccine group (N).
c Non-inferiority of the cPAD group with respect to the single-dose vials group
was demonstrated, as the lower limits of the CI of the differences in seroconversion/
seroprotection rates between the two groups were simultaneously greater than
10% for the ﬁve parameters.
d The 95% two-sided CIs for the difference in seroconversion/seroprotection rates
are constructed based on the Newcombe–Wilson score method.
Table 4
Ratio of geometric mean concentration and geometric mean concentration fold-
increases for the antibody titers: ATP populationa,b
Antigen cPAD
(N = 196)
n (%)
Single-dose
(N = 197)
n (%)
Ratio,
cPAD/
single-dose
Anti-Hib PRP concentration
Pre-vaccination GMC 0.38 0.43
Post-vaccination GMC 4.42 4.24
GMC fold-increase 11.51 9.86
Ratio of GMC fold-increasec 1.167
GMC ratiod 1.042
Anti-diphtheria concentration
Pre-vaccination GMC 0.067 0.066
Post-vaccination GMC 1.53 1.545
GMC fold-increase 22.79 23.31
Ratio of GMC fold-increasec 0.978
GMC ratiod 0.992
Anti-tetanus concentration
Pre-vaccination GMC 1.230 1.266
Post-vaccination GMC 1.11 1.234
GMC fold-increase 0.902 0.974
Ratio of GMC fold-increasec 0.925
GMC ratiod 0.899
Anti-hepatitis B concentration
Pre-vaccination GMC 5.4 4.9
Post-vaccination GMC 149.4 138.5
GMC fold-increase 27.5 28.5
Ratio of GMC fold-increasec 1.0
GMC ratiod 1.1
Anti-Bordetella pertussis concentration
Pre-vaccination GMC 4.6 4.6
Post-vaccination GMC 38.6 42.7
GMC fold-increase 8.3 9.4
Ratio of GMC fold-increasec 0.9
GMC ratiod 0.9
ATP, according-to-protocol; CI, conﬁdence interval; cPAD, compact preﬁlled auto-
disabled system; GMC, geometric mean concentration; Hib, Haemophilus inﬂuenzae
type b; PRP, polyribosylribitol phosphate.
a N is the number of infants with non-missing antibody titer results at both pre-
and post-vaccination.
b GMCs and 95% CIs were calculated by taking the anti-log10 of the means and
95% CIs of the log-transformed pre- and post-vaccination hemagglutination
inhibition titers. The GMC fold-increases and 95% CIs were calculated by taking the
anti-log10 of the means and 95% CIs of the log-transformed fold-increases in post-
vaccination antibody titer over pre-vaccination antibody titer.
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upper respiratory tract infection (24.0%, cPAD; 26.5%, single-dose
vial), rhinitis (7.5% each in the cPAD and single-dose vial groups),
and nasopharyngitis (7.0%, cPAD; 6.0%, single-dose vial). In total,
85 (42.5%) infants in the cPAD group experienced unsolicited AEs
assessed as related to study vaccine, compared with 84 (42.0%)
infants in the single-dose group. The most common unsolicited AE
considered vaccine-related was pyrexia (42.5%, cPAD; 41.5%,
single-dose vial).Table 3
Seroprotection/seroconversion rate: ITT populationa,b
Seroprotection/
seroconversion
cPAD
(N = 197)
n (%)
Single-dose
(N = 198)
n (%)
Diff. (95% CIc)
Hib
Baseline (day 1) 138 (70.1) 153 (77.3)
Visit 4 (day 85) 194 (98.5) 195 (98.5) 0.0 (3.04, 3.01)
Diphtheria
Baseline (day 1) 46 (23.4) 39 (19.7)
Visit 4 (day 85) 197 (100) 196 (99.0) 1.0 (1.04, 3.61)
Tetanus
Baseline (day 1) 182 (92.4) 190 (96.0)
Visit 4 (day 85) 197 (100) 198 (100) 0.0 (1.91, 1.90)
Hepatitis B
Baseline (day 1) 54 (27.4) 51 (25.8)
Visit 4 (day 85) 183 (92.9) 184 (92.9) 0.0 (5.31, 5.23)
Pertussis
Visit 4 (day 85) 188 (95.4) 192 (97.0) 1.5 (5.75, 2.50)
CI, conﬁdence interval; cPAD, compact preﬁlled auto-disabled system; Hib,
Haemophilus inﬂuenzae type b; ITT, intention-to-treat.
a ITT population: The set of all randomized infants who received at least one
injection of the study vaccine and had a post-baseline measurement for at least one
antigen.
b N is the total number of infants in each group and n is the total number of
infants meeting the event. Percentages are based on the total number of infants in
each vaccine group (N).
c The 95% two-sided CIs for the difference in seroconversion/seroprotection rates
are constructed based on the Newcombe–Wilson score method.
c Ratio of GMC fold-increase = GMC fold-increase for cPAD/GMC fold-increase for
single-dose.
d GMC ratio = post-vaccination GMC for cPAD/post-vaccination GMC for single-
dose.No deaths were reported during the study. Eight infants
experienced eight SAEs: pneumonia (n = 3), measles pneumonia
(n = 3), idiopathic thrombocytopenic purpura (n = 1), and an
umbilical abscess (n = 1). Five occurred in the cPAD group and
three in the single-dose group; none were considered related to the
study vaccine. No infants were withdrawn from the study due to an
AE/SAE.
4. Discussion
Preventing bacterial and viral infections in infants via vaccina-
tion remains an ultimate public health goal. Quinvaxem in a new
presentation  the cPAD injection system  is expected to reduce
procedural steps, vaccination process time, and storage needs, and
to minimize vaccine wastage as compared to conventional
administration with a syringe. In the present study, the immuno-
genicity of Quinvaxem in cPAD was shown to be non-inferior to
single-dose vials in infants aged 42 to 64 days, in terms of
seroprotection/seroconversion rates for all antibodies at 1 month
after the primary vaccination course. Both presentations were
well-tolerated. Previous clinical studies have shown that Quin-
vaxem, as a combination of ﬁve antigens, can be administered
Table 5
Responder rate differences and 95% conﬁdence intervals: ATP populationa
cPAD
(N = 196)
n (%)
Single-dose
(N = 197)
n (%)
Unadjusted for vaccinator
Visit 4 (day 85)
Number of responders 172 (87.76) 176 (89.34)
Difference in rates 1.585
95% CIb (8.01, 4.81)
Adjusted for vaccinator
Visit 4 (day 85)
Number of responders 172 (87.75) 176 (89.34)
Difference in rates 1.594
95% CIc (7.86, 4.68)
ATP, according-to-protocol; CI, conﬁdence interval; cPAD, compact preﬁlled auto-
disabled system.
a N is the total number of infants in each group; n is the total number of infants
meeting the event. Percentages are based on the total number of infants in each
group (N).
b Calculated using the Newcombe–Wilson score method.
c Adjusted rates are derived from the odds ratios from the logistic regression
analysis with vaccinator as a factor; the 95% CI for the difference in rates is based on
the normal approximation.
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nents and has a good safety proﬁle.27–29 However, the safety and
immunogenicity of two different presentations of Quinvaxem had
not been studied to date.
In this study, the seroconversion/seroprotection rates were
similar in the cPAD and single-dose vial groups. The percentages of
infants with seroprotection against Hib PRP, HB, diphtheria, and
tetanus toxoids, and seroconversion against B. pertussis, were
greater than 92% for the cPAD and single-dose vial presentations.
GMCs for all antibodies in both groups exceeded the seroprotec-
tion/seroconversion thresholds by large margins.
In the current study, the baseline antibody concentrations to
Hib were high, with 70.1% of cPAD infants and 77.3% of single-dose
infants seroprotected already above the short-term protective
threshold (0.15 mg/ml). These high antibody titers are thought to
be related to high maternal anti-Hib PRP concentrations, as
previously reported from countries with low coverage for Hib
vaccination.14,15,30 This is further supported by data from a study inTable 6
Solicited and unsolicited adverse events (after ﬁrst, second, and third vaccine doses co
Solicited AEs
Infants with at least one solicited AE 
Infants with at least one local event 
Infants with erythema 
Infants with induration 
Infants with tenderness 
Infants with at least one systemic event 
Infants with fever (38 8C) 
Infants with high fever (39.5 8C) 
Unsolicited AEs
Infants with at least one unsolicited AE 
Infants with at least one unsolicited AE assessed as related to study vaccine 
Crying 
Pyrexia 
Infants with at least one serious AE 
AE, adverse event; cPAD, compact preﬁlled auto-disabled system.
a N is the total number of infants in each group; n is the total number of infants mee
group (N).
b All solicited and unsolicited AEs observed after the ﬁrst vaccine dose and up to the las
vaccination.
c The risk differences are presented in percentages.which cord blood anti-Hib IgG concentrations in the infants of Hib–
T recipient mothers were found to be 61% of the maternal
concentrations, and geometric mean anti-Hib antibody concentra-
tions in the vaccinated infants of vaccinated mothers at birth and at
2 and 5 months of age were markedly higher than those in the
vaccinated infants of unvaccinated mothers. At the age of
2 months, 60% of the infants of the vaccinated mothers and 26%
of those of unvaccinated mothers had anti-Hib antibody concen-
trations considered to be protective (>0.15 mg/ml).31 In the
current study, post-vaccination there was a robust increase in
Hib antibody titers in both vaccine groups, indicating a good
immune response to the Hib component of the Quinvaxem vaccine.
Pertussis seroconversion rates were comparable in the two
vaccine groups, with more than 95% achieving at least a 4-fold
increase in antibody titers in the cPAD and single-dose vial groups;
similar results have been obtained in other studies, but with
signiﬁcantly lower geometric mean titers.14,28 In many industrial-
ized countries, the DTP-based combination vaccines incorporate
acellular pertussis (aP). For several decades, inactivated whole-cell
pertussis (wP) vaccines have been part of the national childhood
vaccination programs, dramatically reducing the considerable
public health impact of pertussis. Frequent, but usually mild
adverse reactions, and a fear of rare but serious acute or chronic
neurological events associated with wP vaccination, prompted the
development of a new generation of pertussis vaccines, the aP
vaccines, which are believed to have fewer such reactions than wP
vaccines.27,32 However, evidence suggests that licensed aP
vaccines have lower initial efﬁcacy, faster waning of immunity,
and possibly a reduced impact on transmission compared with
current internationally available wP vaccines.33,34 Mathematical
modeling studies and baboon models support the hypothesis that
transition from wP to shorter duration of protection aP may be
associated with disease resurgence.35,36
The tetanus toxoid antibody pre/post-vaccination ratios were
0.90 and 0.97 for the cPAD and single-dose groups, respectively.
For both groups, 100% long-term tetanus seroprotection was
obtained. Long-term seroprotection is indicated by an antibody
concentration of 0.1 IU/ml; the concentrations for cPAD and
single-dose groups post-vaccination were 1.11 and 1.23 IU/ml,
respectively, with a post-vaccination concentration of 1.11 IU/ml,
well above the cut-off of 0.1 IU/ml as recommended by the WHO.37mbined)a,b
cPAD
(N = 200)
n (%)
Single-dose
(N = 200)
n (%)
Risk difference,c
cPAD  single-dose
difference
185 (92.5) 184 (92.0) 0.5
175 (87.5) 169 (84.5) 3.0
52 (26.0) 61 (30.5) 4.5
74 (37.0) 76 (38.0) 1.0
171 (85.5) 153 (76.5) 9.0
85 (42.5) 83 (41.5) 1.0
85 (42.5) 83 (41.5) 1.0
1 (0.5) 8 (4.0) 3.5
131 (65.5) 138 (69.0) 3.5
85 (42.5) 84 (42.0) 0.5
0 1 (0.5) -0.5
85 (42.5) 83 (41.5) 1.0
5 (2.5) 3 (1.5) 1.0
ting the event. Percentages are based on the total number of infants in the vaccine
t safety follow-up are included. Solicited AEs include data collected 30 min after each
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immunization. These concentrations are known to vary depend-
ing on the characteristics of the population in which the study is
performed and have an impact on the observed pre/post-
vaccination GMC increase.38,39 Tetanus toxin maternal anti-
bodies decay with an average half-life of 48 days.40,41 At an age
of 4 months, an infant has around 10% of the original maternal
antibody concentration circulating in the blood. From the half-
life, it can be concluded that a GMC fold-increase of 0.10 is
derived from antibodies produced by the infants indicative of a
vaccine response. Even if a mathematical correction model was
used to correct for the maternal antibody concentrations, the
vaccine response of the infants in the present study was still well
above the required antibody concentration level for long-term
protection.
As per the WHO recommendation, four vaccinators were
included in this study to assess whether any differences in
immunogenicity were observed when various vaccinators admin-
istered Quinvaxem in cPAD. Logistic regression analysis on
seroconversion/seroprotection rates at visit 4 adjusted for
vaccinator did not reveal any effect of the vaccinator. Moreover,
the unadjusted seroprotection/seroconversion rates for each
antigen were the same as the rates adjusted for the vaccinator.
Overall, both vaccines were well-tolerated and most of the local
and systemic reactions were mild-to-moderate. The incidence of
solicited or unsolicited AEs was largely consistent with previous
studies and similar in the two groups.14,15,28,29 Tenderness, the
most common solicited local AE, was reported at 9% higher
incidences in the cPAD group than in the single-dose group.
However, injection site induration and erythema were observed at
similar or lower frequencies in the cPAD group compared with the
single-dose group. Overall, both presentations were well tolerated.
Quinvaxem in cPAD is a widely used fully liquid pentavalent
vaccine that is available in a single-dose vial, with the only difference
being its compact, preﬁlled, auto-disable injection system and
secondary packaging. The new presentation, cPAD, might help to
increase vaccine coverage, especially in hard-to-reach situa-
tions,15,42 because it simpliﬁes transport and logistics by being
lightweight,43 with a small volume,43,44 safe disposal,29,42 easy to
use presentation simplifying vaccine administration,15,20,21,42 and
reducing handling errors.15,19,45,46 It also offers several other
beneﬁts including reduced missed vaccination opportunities due
to mismatch between vaccine doses and consumables (needles and
syringes) as all required components are present at the same place
and time,29,42,43 increased vaccine coverage by reducing vaccination
time (six times quicker administration versus a single-dose
lyophilized vial),21 and less vaccine wastage45,47–49 as the single-
dose presentation ensures opened multi-dose vials are not
discarded. The contamination risk is also expected to be minimized
as vaccine sterility is maintained right up to the point of
administration,42,45 and the auto-disable feature prevents needle
and syringe reuse.29 These beneﬁts of cPAD can potentially improve
vaccination program performance by facilitating increased vaccina-
tion coverage in many countries.
This study aimed to demonstrate non-inferiority of three doses
of Quinvaxem in cPAD to three doses of Quinvaxem in single-dose
vials with respect to immunogenicity. The study was performed at
a single research site where the vaccinators were properly trained.
It will be important to assess the acceptability and continue to
collect further safety data when the new presentation is
administered by health workers as part of the EPI program.
In conclusion, non-inferiority of three doses of Quinvaxem in
cPAD to three doses of Quinvaxem in single-dose vials was
demonstrated with respect to seroprotection/seroconversion rates
for all antibodies (anti-HBs, anti-Hib PRP, anti-diphtheria,
anti-tetanus, and anti-B. pertussis) at 1 month after completion ofthe 6–10–14 week schedule. The overall safety proﬁles of the two
presentations were similar.
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